January 8, 2019
Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to other therapies. The decision by the Therapeutic Goods Administration (TGA) means that myeloma patients in Australia will be the first to have access to this medication. Specifically, Aplidin was approved for patients who relapsed after three lines of...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand